All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Namodenoson
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: CF102
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 16, 2020
Details:
Anti-Inflammatory effect – a significant decrease in the liver enzymes ALT and AST and significant improvement in the positive cytokine adiponectin was recorded in the Namodenoson 25 mg treated group.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Namodenoson
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: CF102
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2020
Details:
In a Phase II NASH/NAFLD study, Namodenoson at the 25 mg dose produced statistically significant results showing anti-inflammatory, anti-steatotic, and anti-fibrosis effects in the liver, while also having a strong safety profile and being well tolerated.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): CM-101
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: CM-101
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 19, 2020
Details:
In the Phase Ib study in NAFLD patients, CM-101, a novel, first-in-class, CCL24 neutralizing antibody decreased serum biomarkers of fibrosis and inflammation with an excellent safety profile and tolerability.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Namodenoson
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: CF102
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 30, 2020
Details:
Can-Fite’s Phase II NAFLD/NASH dose-finding study, assessing the efficacy and safety of Namodenoson (CF102), achieved its endpoints in a dose dependent and statistically significant manner.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): CM-101
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: CM-101
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 26, 2020
Details:
European Commission has granted Orphan Drug Designation to Chemomab's lead drug candidate CM-101 for the treatment of Primary Sclerosing Cholangitis (PSC), based on a positive opinion from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Namodenoson
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: CF102
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 25, 2020
Details:
Patent claims include use of the A3 adenosine receptor (A3AR), the target of Can-Fite’s platform technology, in reducing ectopic fat accumulation particularly in fatty liver as manifested in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
